Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.

African American male_patient

The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA (US) site dedicated to smallpox vaccine production since 1882. Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza.

Our Vaccines business has a portfolio of more than 40 vaccines for every stage of life, helping to protect people against 22 diseases. We have a pipeline of 14 candidate vaccines in development. One third of our vaccines in development target diseases particularly prevalent in the developing world, including all three WHO infectious disease priorities: HIV, malaria and TB. Our other vaccines in development include vaccines for the treatment of COPD and prevention of Respiratory Syncytial Virus (RSV). In October 2017, our shingles vaccine, Shingrix, received regulatory approval in Canada and the US.

The business generated sales of $6.7 billion in 2017, representing 17% of the total turnover of the Group.

Our marketplace 

Vaccination is recognized worldwide as one of the best investments that any government or healthcare organization can make. In 2012, the WHO and its 194 member’s states published an action plan on vaccination to extend access to immunization to everyone in the world, promote innovation in the vaccines industry and prevent millions of deaths. 

This plan involves more equitable access to existing vaccines for people in all communities, the introduction of new and improved vaccines and accelerated research and development for the next generation of vaccines and technologies. Overall, this should translate into a growing global demand for vaccines over the next 10-15 years.

For example, more than 25 million children are born every year in India alone and it’s estimated that by 2020 there will be more than a billion people in the world aged over 60.

Our strategy

Our strategy is to bring differentiated, high-quality, and needed vaccines to as many people as possible.

To do this we focus on creating a strong patient and payer focused pipeline, maintaining valuable partnerships with our local operating countries, and ensuring sustainable access and affordability.

Quality and manufacturing

In 2017, we sold more than 798 million doses of vaccine around the world. These are made in one of our 16 manufacturing sites located around the world. For some of our vaccines, this production process can take up to two years.

On average, each batch of vaccine will have undergone more than 100 quality checks before it is sent out, to ensure the vaccines meet world-class standards. Each of our vaccines is produced to the same quality standard, regardless of where in the world the vaccine will be used. 

We are continuously investing in our manufacturing facilities, improving our processes and building partnerships to ensure we meet the global growing needs for high quality vaccines.

Research and collaboration

Innovation is the beating heart of our business. Without it, there will be no new vaccines for the many diseases that still threaten individuals, families and communities around the world.

Our R&D organization brings together expertise in virology, bacterial infection and different adjuvant platforms. We now have three global R&D hubs: Rockville, MD (US) (new in 2015); Rixensart, Belgium and Siena, Italy, which are focused on discovering and developing novel vaccines across a range of pressing public health threats. Our efforts are concentrated on those possible vaccines which may offer significant improvements over existing options or target diseases for which no vaccines yet exist. 

Our approach is to make the most of our own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Our vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. We have much to offer and through collaboration we can achieve so much more.

For example, more than 90% of the vaccines in our pipeline are being developed in partnership with others. We have a long track record of collaborating with governments, healthcare providers, regulators, academic institutions, non-governmental organizations, vaccine producers and other key partners to tackle public health challenges around the world.

Working together to raise adult immunization rates

Adult immunizations have the potential to improve public health and save money to the healthcare system. Adult immunization rates remain low, despite being recommended by the Centers for Disease Control and Prevention and the medical and public health community.[i]

As part of a collaboration with leading healthcare stakeholders, GSK released the Vaccines and Quality Roadmap: Using Healthcare Quality Levers to Increase Adult Immunization Rates in the US (PDF 649kb) that – outlines a series of recommendations to increase immunization rates among adults.

GSK and the decade of vaccines

The Decade of Vaccines Collaboration and the Global Vaccine Action Plan Download PDF

decade of vaccines_children

[i] Centers for Disease Control and Prevention. “National Early-Season Flu Vaccination Coverage, United States, November 2017.” Available at Accessed March 2018.